Boston Scientific stock is under fresh scrutiny as analysts adjust their price targets upward. The consensus figure is now $126.14, up from $124.53. This incremental rise reflects optimism fueled by strong quarterly results and revised guidance, balanced against an evolving competitive landscape. Read on to discover how you can stay ahead of future updates as the narrative around Boston Scientific continues to develop.

Analyst sentiment on Boston Scientific remains largely positive, with price target increases reflecting confidence in the company’s execution and growth outlook. However, there are also some tempered views on valuation and potential near-term risks.

???? Bullish Takeaways

Truist raised its price target to $130 from $129 and kept a Buy rating. The firm highlights Boston Scientific's strong Q3 earnings beat, particularly noting accelerating Watchman growth as a standout. Truist remains confident that the company can deliver upside even to the higher guidance now in place.

Morgan Stanley increased its price target to $130 from $125 and maintains an Overweight rating. The firm made modest model adjustments following strong Q3 results and updated guidance, pointing to the company’s long-range targets as positive drivers.

Goldman Sachs raised its target to $124 from $120 and emphasized Boston Scientific’s ability to sustain sales and earnings per share (EPS) growth above large-cap MedTech peer averages. The firm updated business mix and cash flow projections, underlining confidence in above-average performance.

Barclays moved its price target to $136 from $133 and referenced the company’s impressive three-year growth plan targeting 10% organic growth, supported by a broad range of programs. The firm sees significant upside for shares.

Evercore ISI lifted its target to $113 from $110 and keeps an Outperform rating, noting that recent results allayed earlier fears around share losses in electrophysiology. The post-earnings rally in shares is seen as justified.

Leerink reiterated an Outperform rating and highlighted the strategic acquisition of Nalu Medical alongside management’s track record of executing favorable early-stage investments.

Truist previously boosted its target to $129 from $125 following the Investor Day presentation, citing Boston Scientific’s best-in-class pipeline and above-average growth potential.

Oppenheimer raised its price target to $118 earlier in the year and reflected an updated outlook post-Q2 results.

Across the bullish commentary, analysts point to strong execution, consistent delivery above guidance, and successful pipeline management as primary drivers of optimism. Reservations regarding valuation and whether recent upside is already reflected in the share price are occasionally noted but do not dampen overall constructive sentiment.

???? Bearish Takeaways

Erste Group downgraded Boston Scientific to Hold from Buy due to concerns that sales growth will be lower in 2026 compared to 2025. The firm also cautions that the stock trades at a premium relative to peers and suggests limited upside from current levels.

The more cautious views mainly relate to questions around future growth moderation and valuation, with the suggestion that much of the upside may now be priced in.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Truist increased Boston Scientific's price target to $130 from $129 after a strong third quarter earnings report. The firm cited especially rapid growth in the Watchman product line and remains optimistic about further upside to the company’s updated guidance.

Oppenheimer raised its price target to $118 from $110 following the second quarter earnings report, maintaining a Perform rating and reflecting an improved outlook post results.

Boston Scientific released guidance for the fourth quarter and full year 2025, forecasting robust net sales growth of 14.5% to 16.5% in Q4 and approximately 20% for the full year. The company expects GAAP earnings per share between $1.97 and $2.01 for 2025.

The company recently convened an Analyst and Investor Day, highlighting long-term financial targets and strategies for sustained growth across its business segments.

The consensus analyst price target has risen slightly to $126.14 from $124.53.

The discount rate increased marginally, now at 7.60% compared to 7.56% previously.

Revenue growth projections have edged lower, now estimated at 11.04%, down from 11.14%.

The net profit margin improved, rising to 19.27% from 18.71%.

The future P/E ratio has fallen moderately, now at 46.32x compared to the previous 49.09x.

Narratives give you the story behind the numbers, linking real-world events and insights to future forecasts and fair value. By connecting a company’s journey to its financial estimates, Narratives on Simply Wall St help you see when price and value no longer align. They are easy to follow, update dynamically as news or earnings break, and are trusted by millions in the Community page to make smarter buy or sell decisions.

Read the original Boston Scientific Narrative for unique insight and stay ahead of the curve: Future Growth Plans And Acquisitions Will Drive Broader Market Expansion

Breaks down how innovation and acquisitions will drive Boston Scientific’s next phase of market growth.

Analyzes updated analyst forecasts, covering revenue, earnings, margins, and fair value.

Identifies key risks, catalysts, and what could move the share price in either direction.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BSX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com